How IQVIA and Veeva Are Improving Efficiency and Data Management in Clinical Trials

In a recent interview with Applied Clinical Trials, Paul Shawah, EVP of Strategy at Veeva Systems, and Richard Staub, President of R&D Solutions at IQVIA, discussed their companies’ new global clinical and commercial partnership. Designed to simplify and accelerate clinical trials, the collaboration aims to maximize value for customers by integrating software, data, and services from both organizations. Early feedback has been overwhelmingly positive, underscoring the partnership’s potential to streamline workflows, enhance data quality, and support both traditional and decentralized clinical trial models, ultimately helping sponsors bring therapies to market faster.

ACT: What advantages will trial sponsors see from the combined use of IQVIA’s clinical technology solutions and Veeva’s software ecosystem?

Staub: Holistically, our goal is to bring the best technologies to every clinical trial we run for sponsors. We look for solutions that can easily plug and play, integrating seamlessly into the trial workflow. Veeva’s platform offers not only a strong technology foundation but also the flexibility to incorporate other solutions when needed, providing a unified view of the data. Ultimately, the ecosystem allows us to combine the best tools for any given study, which is what sponsors benefit from most.

Shawah: Richard summed it up perfectly. This partnership is about speed, simplicity, and bringing together the best technology with the best services. But it’s not just technology—it’s also about process. By combining IQVIA’s extensive trial expertise with advanced technology, we can streamline clinical development, reduce timelines, and ultimately get medicines into patients’ hands faster.

Full Interview Summary: IQVIA and Veeva have launched a new global clinical and commercial partnership aimed at simplifying and accelerating clinical trials while maximizing value for customers. The primary goal of the collaboration is customer success—enabling clients to seamlessly access and use software, data, and services from both companies in an efficient, integrated manner. Early feedback on the partnership has been overwhelmingly positive, highlighting its potential to deliver both near-term and long-term benefits.

On the commercial side, the agreement allows customers to combine technologies from IQVIA and Veeva easily. IQVIA has joined Veeva’s technology and services partner programs as an AI partner, opening opportunities for its data to enhance Veeva products, including AI-driven applications. Clinically, IQVIA can leverage Veeva’s full suite of applications, such as Veeva EDC, to streamline study builds and trial execution. By combining the strengths of both organizations, the partnership aims to simplify workflows, improve compliance, and speed up data collection and cleaning, enabling sponsors to bring therapies to market faster.

The collaboration enhances clinical data management by integrating IQVIA’s CRO expertise with Veeva’s technology platforms. This “plug-and-play” approach allows trial sponsors to use the best-fit technologies for each study, improving efficiency and data quality. Sites benefit from user-friendly systems that encourage timely data entry, while sponsors gain faster access to clean, locked data for regulatory submission or progression to the next development phase.

Looking ahead, the partnership is positioned to support decentralized and hybrid trials, where technology interfaces directly with patients in addition to traditional sites. By combining operational expertise with advanced technology, IQVIA and Veeva aim to enable flexible, patient-centric studies that reduce timelines, improve research efficiency, and create new opportunities for innovation in clinical trial design.